Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

After Seven Years Device Tax Repeal Looks Certain

Executive Summary

US lawmakers have agreed on a bipartisan budget to prevent a government shutdown that includes repealing the medical device tax. If all goes according to plan, the bill -- which was approved by the House on 17 December and is now headed to the Senate -- is expected to be on the president’s desk for signing by the end of the week.

You may also be interested in...



Trump Signs Bill Bolstering US FDA Device Center Funding By 2% To $8M

The FDA’s device center is getting a 2% boost after President Trump on 20 December signed off on all appropriations bills for fiscal year 2020.

LAB Act Included In Must-Pass, US 2020 Appropriations Bill Legislation Due To Be Signed By 20 December

The US Congress and President Donald Trump are expected to clear and sign off on the Laboratory Access for Beneficiaries Act favored by the clinical laboratory industry and manufacturers of in vitro test kits, as part of a must-pass appropriations bill intended to keep the US government open and funded for the balance of the 2020 fiscal year.

AdvaMed Chair: Another Device Tax Moratorium More Likely Than A Full Repeal

As the top medtech lobby groups continue to push for a permanent repeal of the medical device excise tax, one of their top lobbyists and medtech executives says it’s far more likely they will see another multiyear moratorium considering the political reality.

Related Content

Topics

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel